Deerfield Management Company, L.P. (Series C) Inozyme Pharma, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.33 - $7.31 $50,189 - $84,730	11,591 New	11,591 $51,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $1.56 Million - $3.3 Million	-605,936 Reduced 22.47%	2,090,436 $5.6 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.96 $1.13 Million - $2.1 Million	351,586 Added 14.99%	2,696,372 $12.9 Million
Q3 2021 Nov 15, 2021	BUY	$11.12 - $19.4 $1.84 Million - $3.22 Million	165,801 Added 7.61%	2,344,786 $27.2 Million
Q2 2021 Aug 16, 2021	BUY	$15.19 - $21.2 $3.27 Million - $4.56 Million	214,985 Added 10.95%	2,178,985 $37.1 Million
Q1 2021 May 17, 2021	BUY	$17.77 - $27.9 $14.5 Million - $22.7 Million	813,701 Added 70.74%	1,964,000 $38.9 Million
Q3 2020 Nov 16, 2020	BUY	$17.54 - $30.2 $20.2 Million - $34.7 Million	1,150,299 New	1,150,299 $30.2 Million

Others Institutions Holding INZY

# of Institutions

Shares Held

53M

Call Options Held

3.7K

Put Options Held

5.8K

Adage Capital Partners Gp, L.L.C. Boston, MA

5.67M
Shares

$16.6 Million
0.05% of portfolio
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA

4.49M
Shares

$13.2 Million
18.53% of portfolio
Sofinnova Investments, Inc. Menlo Park, CA

4.28M
Shares

$12.5 Million
2.12% of portfolio
Eventide Asset Management, LLC Boston, MA

4.13M
Shares

$12.1 Million
0.38% of portfolio
Rock Springs Capital Management LP Baltimore, MD

3.8M
Shares

$11.1 Million
0.68% of portfolio

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account